82 results about "Vascular inflammation" patented technology

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases / conditions or risk factors therefore.

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF.

The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and / or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

A method and apparatus for treating gum disease includes a light producing dental appliance that is accessible exteriorly of the body for placement within the mouth of the patient to expose the mouth to light radiation of a selected wavelength and in an amount that is effective for killing or debilitating pathogenic microorganisms and especially Porphyromona gingivalis within the mouth of the patient such that the bacterial load carried to the heart is diminished thereby reducing or eliminating the symptoms of coronary artery disease, atherosclerosis vascular inflammation and plaque formation.

The present invention also provides methods and compositions for imaging and evaluating, e.g., blood flow or inflammation in a subject. Such evaluations are important in a number of clinical diagnoses, including assessing organ damage associated with angina pectoris, heart attack, stroke, cancer, atherosclerosis, and the like, as well as assessing vessel leakages associated with aneurisms, diffuse bleedings after trauma, and the like.

The invention relates to application of sodium alginate oligose and a derivative to treatment of inflammations. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond. The inflammations are particularly a vascular inflammation, a neuroinflammation, a nervous centralis inflammation, arthritis, Crohn's disease, ulcerative colitis, inflammatory diabetic ulcer, psoriasis, atopic dermatitis and eczema.

The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.

The present invention relates to methods of using lactoferrin (LF) to reduce circulating levels of cholesterol and vascular inflammation, in order to treat, prevent or reduce the incidence of atherosclerosis and cardiovascular disease.

The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and / or BMPR-II, in an amount sufficient to for inhibiting or reducing vascular inflammation by interfering with binding of bone morphogenic protein or a fragment thereof to bone morphogenic protein receptors. Exemplary BMP antagonists include polypeptides having an eight-, nine-, or ten-membered ring cystine knot structure. Representative BMP antagonists include, but are not limited to the CAN family of proteins, the chordin family that includes chordin and ventroptin, and noggin.

The invention provides a pure Chinese traditional medicine preparation for treating psoriasis and multiple skin diseases. The pure Chinese traditional medicine preparation is prepared from the following 21 Chinese traditional medicinal materials: honeysuckle flowers, cortex phellodendri chinensis, flos chrysanthemi indici, glabrous greenbrier rhizome, common ducksmeat herb, yam rhizome, radix rehmanniae, zaocys dhumnade and the like. The pure Chinese traditional medicine preparation provided by the invention has the effects of dispelling wind and nourishing blood, removing dampness to relieve itching, removing pathogenic heat from the blood and toxic materials from the body and supporting the healthy energy, has good treatment effects on the allergic reaction, epidermis proliferation cornification, lichenification, vascular inflammation and hair follicle and sebaceous gland blockage, such as the psoriasis (psora), leucoderma, neurodermatitis, dermatitis, eczema, urticaria, irritability, rubella, comedo, acne and verruca plana, is wide in clinical application treatment range without toxic and side effects, and can not injure the organs and functions of a human body and enhance the physique and the immunity of the human body even if being taken for a long time. A medicament prepared through a preparation method of the pure Chinese traditional medicine preparation is high in dissolution rate and higher in stability.

The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and / or symptoms associated with systemic and / or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and / or analog thereof.

Described herein are compositions, methods, therapies, strategies, techniques and processes for treating vascular inflammation in blood vessels by administering a photo-activatable compound and low light fluence in the range of about 10 to about 400 Joules / cm of illuminated length in the general vicinity of the inflammation.

A method for the prevention and / or treatment of a disease accompanied by vascular leakage and / or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.

The invention relates to the technical field of cosmetics, in particular to a facial treatment mask with the antibacterial and moisturizing functions and a making method thereof. Nano-silver with high antibacterial and sterilizing effects is adopted, the nano-silver and anti-inflammation ingredients including allantoin, dipotassium glycyrrhizinate and D-panthenol in a formula supplement one another, and therefore bacteriostatic and antibacterial capacities of the product are improved; the nano-silver and moisturizing ingredients including sodium hyaluronate, betaine and glycerin in the product act synergistically, the skin is recovered to be moist and bright, and meanwhile small blood vessels or inflammations or acne of the facial skin can be rapidly repaired.

Provided are a pharmaceutical composition containing a 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative represented by Formula 1 as an active ingredient and a use thereof effective on a vascular inflammation-related infectious disease triggered by activity of HMGB1 protein.As investigating an anti-sepsis effect through a CLP-induced sepsis animal test that a sepsis survival rate is increased, it is identified that the pharmaceutical composition contains the 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative or a pharmaceutically available salt thereof as an active ingredient to be used as a therapeutic agent for a vascular inflammatory disease and infectious disease including sepsis triggered by activity of HMGB1 protein.

The present invention describes a new functional biomarker of vascular inflammation and its use in predicting all-cause or cardiac mortality. The invention also provides a method for stratifying patients according to their risk of all-cause or cardiac mortality using data gathered from a computer tomography scans of a blood vessel to determine a specific combination of structural and functional biomarkers of vascular inflammation and disease.

The present invention concerns a human resistin receptor. More particularly, the present invention provides a method for screening a receptor of human resistin protein, a method for preventing or treating an inflammatory disease and arteriosclerosis using an expression- or activity-regulator for a human resistin receptor, and a pharmaceutical composition including an expression- or activity-regulator for the human resistin receptor. The method for screening a human resistin protein receptor according to the present invention enables separation of a receptor which directly binds to resistin from human monocyte, reveals a mechanism of signal transduction of the resistin receptor, and therefore, is expected to contribute to regulation of an inflammatory effect of monocyte, molecular detection of causes for vascular inflammation and arteriosclerosis, and developments of prevention and a treating agent for an inflammatory disease and arteriosclerosis.

The invention discloses application of NW (Norswertianolin) in preparing a drug for preventing or treating diseases related to a CSE (Cystathionine gamma-Lyase) / H2S system. An inventor discovers thatNW is capable of combining CSE, promoting CSE enzyme activity and increasing generation of heart, blood vessel and kidney endogenous H2S, and is a new CSE enzyme activator. The NW is capable of activating a blood vessel CSE / H2S system, remarkably reducing high blood pressure, reducing vascular remodeling, inhibiting vascular inflammation, reducing atherosclerotic plaque, activating a kidney CSE / H2S system and reducing kidney ischemia reperfusion injury, so that the NW can be used for treating the diseases related to CSE / H2S.

Described are methods of decreasing vascular inflammation in a subject suffering from a chronic autoimmune or chronic inflammatory disease by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg / day to about 160 mg / day, optionally administered in two daily sub-doses. Also described are methods of treating inflammation associated with an implant (e.g., a breast implant) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg / day to about 160 mg / day, optionally administered in two daily sub-doses. Further described are methods of treating psoriasis (e.g., active plaque psoriasis) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 80 mg / day to about 160 mg / day, optionally administered in two daily sub-doses.

The invention relates to the technical field of cosmetics, in particular to an antibacterial and moisture preservation mask with the mild touch sense and a manufacturing method thereof. Glycerol contents are not added in a product; after the face is coated with the mask, the touch sense is mild but not sticky or greasy; under the effects of emulsifying and thickening ingredients such as acrylic ester / vinyl isodecanoate crosslinked polymers, dimethicone, carbomer and butanediol, after the still standing for 4 to 8 h after the coating of the product, the surface layer is in a half solidified state; the influence of the product on bedding, mattress and pillows under unconscious actions during deep sleeping can be reduced. In addition, through the use of nanometer silver with strong antibacterial and bactericidal effects, the complementary effect is achieved with allantoin, and D-panthenol antibacterial and bactericidal ingredients in the formula, so that the antibacterial and bactericidalcapability of the product is improved. The synergistic effect is achieved with moisture preservation ingredients of trimethylglycine trimethylglycocoll, phycite, sodium hyaluronate and the like in the product; the skin fine blood vessels, inflammation or acne are fast restored; meanwhile, watery and glossy states are restored.

The invention belongs to the field of medicines or health products, and particularly relates to the use of catechin and epicatechin compounds in the preparation of drugs for up-regulating the expression level of microRNA-126. As found by researches, catechin, catechin gallate, gallocatechin, (-)-gallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallatecan up-regulate the expression level of the microRNA-126, and can be used for treating tumors, asthma, inflammatory bowel disease, vascular inflammation, hypertension, type 2 diabetes mellitus, diabetic nephropathy or diabetic retinopathy.

The invention relates to a tea bag for reducing blood glucose and a preparation method thereof. The tea bag for reducing the blood glucose contains following constituents of, in percentage terms, 45%-55% of green bonnie flowers, 10-15% of Chinese yam, 5%-10% of corn stigma, 5%-10% of ginseng, 3%-5% of fel ursi, 5%-10% of lily and the balance medlar. The preparation method of tea bag for reducing the blood glucose includes following steps: A, drying the green bonnie lowers; B, removing peels and fibrous roots of the Chinese yam, and slicing and drying the Chinese yam; C, drying the corn stigma; D, washing fresh ginseng thoroughly, cutting off the ginseng, and drying the ginseng; E, bagging the green bonnie flowers, the Chinese yam, the corn stigma and the ginseng, which are dried, together with the medlar, the fel ursi and the lily so as to obtain the tea bag for reducing the blood glucose. The tea bag for reducing the blood glucose is simple to manufacture, and easy to carry and brew, and has good effects for diabetes, coronary heart disease, hypertension and various vascular inflammations.

Described herein is a method of inducing vascular inflammation using modified paramagnetic nanoparticles with improved therapeutic loading efficiency and enhanced circulation properties. The method comprises loading lipophilic agent into the fatty acid coatings of a paramagnetic nanoparticle (PMNP). In certain embodiment, the lipophilic agent is lipopolysaccharides (LPS). Described herein is a method of inducing vascular leakiness. In certain embodiment, the method induces a significant enhancement of vascular leakiness in a human body. In certain embodiments, the vascular leakiness allows for enhanced local delivery of nanoparticle and non-nanoparticle based therapeutics, imaging agents and theranostics. Also described herein is a method of using the PMNP for the treatment of diseases. In certain embodiments, the method of treatment is a combination therapy. Described herein are imaging of therapeutic delivery of PMNP and diagnostic methods using the PMNP. Also described herein is a diagnostic kit that comprises the PMNP.

The invention discloses a drug coating stent based on HIV protease inhibitor saquinavir. The drug coating stent comprises a base support and a drug coating which coats the surface of the base support, wherein a drug and a base material are contained in the drug coating; the drug comprises saquinavir. The invention also discloses a preparation method of the drug coating stent: adding the polymer base material and the drug to water, and uniformly mixing to prepare uniform colloidal sol; then soaking the base support in the colloidal sol, and then forming a film through drying and curing to obtain the drug coating support. The drug coating stent based on HIV protease inhibitor saquinavir is applied to endovascular intervention operations, and can control vascular inflammation and prevent the occurrence of vascular restenosis.

The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.

The invention discloses a traditional Chinese medicine preparation for preventing and treating coronary artery injury of a kawasaki disease. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 9 parts of root of kudzu vine, 6 parts of salviae miltiorrhizae and 6 parts of ligusticum wallichii. According to the pharmacological action of the primary chemical components of root of kudzu vine, salviae miltiorrhizae and ligusticum wallichii, the traditional Chinese medicine preparation is proved to have the functions of increasing coronary blood-flow volume, improving blood oxygen supply of myocardium, reducing the oxygen consumption of myocardium, improving microcirculation, reducing the surface activity of blood platelets, inhibiting platelet aggregation and preventing thrombogenesis. In traditional Chinese medicine, the root of kudzu vine is a medicine for relieving exterior disorder, and salviae miltiorrhizae and ligusticum wallichii are medicines for invigorating blood circulation and eliminating stasis. The root of kudzu vine, the salviae miltiorrhizae and the ligusticum wallichii are compatible. The preparation meets compatibility principles of various drugs. However, kawasaki disease is systematic vascular inflammation which primarily induces infantile coronary artery injury. The preparation facilitates the preventionand treatment of coronary artery disease of kawasaki disease. The traditional Chinese medicine preparation is reasonable in formula compatibility, remarkable in effect, low in cost, small in side effect, obvious in curative effect after clinical application and worth being popularized.